Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma

Hao Meng Yip; Kwee Yong; Dunnya De-Silva; Neil Rabin

doi:10.1016/j.hemonc.2020.01.001

Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma

Hematol Oncol Stem Cell Ther. 2021 Jun;14(2):160-162. doi: 10.1016/j.hemonc.2020.01.001. Epub 2020 Mar 12.

Authors

Hao Meng Yip¹, Kwee Yong², Dunnya De-Silva², Neil Rabin²

Affiliations

¹ Department of Haematology, University College London Hospitals, London, United Kingdom. Electronic address: meng.yip@nhs.net.
² Department of Haematology, University College London Hospitals, London, United Kingdom.

PMID: 32192978
DOI: 10.1016/j.hemonc.2020.01.001

Abstract

High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is the standard of care for eligible multiple myeloma (MM) patients with improved progression-free and overall survival. We reviewed the ambulatory care unit pathway for MM patients who underwent HDT/ASCT in a tertiary hospital to assess safety efficacy and outcomes. We concluded that the ambulatory care model offered for MM patients undergoing HDT/ASCT is a safe alternative pathway and highlighted further improvements.

Keywords: Ambulatory care; Autologous transplantation; Multiple myeloma; Outpatient; Patient safety.

MeSH terms

Adult
Aged
Ambulatory Care
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Male
Middle Aged
Multiple Myeloma / therapy*
Stem Cell Transplantation / adverse effects*
Transplantation, Autologous / adverse effects*
Treatment Outcome

Substances

Antineoplastic Agents